ArticleBreast (Edinburgh, Scotland)2022

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.

Joseph Gligorov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.